Conferences

RSS

Another antioxidant from Oxis: TX-153

April 5, 1996

BXT-51072 in line for clinical evaluation at Oxis

April 5, 1996

Novel vasoprotectants in AtheroGenics' pipeline

April 5, 1996

PB-005 slated to enter phase II

April 5, 1996

Genentech claims vitronectin antagonists

April 5, 1996

Vitronectin receptor antagonist revealed by SmithKline Beecham

April 5, 1996

New PAF antagonist discovered at Abbott

April 5, 1996

Zeneca selects NMDA antagonist for preclinical study

April 5, 1996

GV-150526A in development for stroke

April 5, 1996

TR-810 delivers SOD to the nervous system

April 5, 1996